The most common AEs after treatment with new-generation covalent BTK inhibitors are neutropenia, thrombocytopenia, rash, bruises, leukopenia, and so on, which can be managed according to the instructions and related guidelines [35, 45]. This evidence concerns the gene BTK and Decreased total neutrophil count.